Context Therapeutics (CNTX), a biopharmaceutical company, on Wednesday, announced the dosing of the first patient in its Phase 1 clinical trial of CTIM-76 in CLDN6-positive gynecologic and testicular cancers.
The trial will enroll up to 70 patients, and initial data is expected to be shared in the first half of 2026.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.